Analyst Price Targets — ARQT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:40 am | Doug Tsao | H.C. Wainwright | $34.00 | $27.01 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $34 at H.C. Wainwright |
| November 28, 2025 11:32 am | Uy Ear | Mizuho Securities | $37.00 | $30.96 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho |
| October 30, 2025 11:29 am | Richard Law | Goldman Sachs | $29.00 | $25.41 | TheFly | Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs |
| October 29, 2025 10:20 am | Douglas Tsao | H.C. Wainwright | $30.00 | $24.95 | TheFly | Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright |
| October 29, 2025 10:11 am | Uy Ear | Mizuho Securities | $32.00 | $24.95 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho |
| March 11, 2025 5:59 pm | — | Jefferies | $19.00 | $15.49 | TheFly | Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies |
| December 30, 2024 11:08 am | Douglas Tsao | H.C. Wainwright | $19.00 | $14.20 | TheFly | Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright |
| May 15, 2024 7:15 am | Serge Belanger | Needham | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Needham |
| May 15, 2024 5:18 am | Uy Ear | Mizuho Securities | $18.00 | $8.13 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho |
| January 2, 2024 4:07 pm | — | Mizuho Securities | $8.00 | $3.43 | StreetInsider | Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $8 at Mizuho Securities, Upgraded to Buy |
Latest News for ARQT
Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis ARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:…
WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.
Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue (+84% YoY) and a GAAP EPS beat, driven by Zoryve's rapid adoption. ARQT is transitioning from a launch-stage biotech to a profitable, high-growth commercial company, with Zoryve now the leading branded nonsteroidal topical in its indications. Valuation is premium at ~9x forward EV/sales but justified by operating leverage, a robust pipeline,…
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.09 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARQT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.